ArticleDrug delivery and translational research2013
Cyclodextrin-based targeting strategies for tumor treatment.
Article in Drug delivery and translational research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 21 citations in OpenAlex.
- Cyclodextrins as Active Therapeutic Agents: Beyond Their Role as Excipients.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Supramolecular nanomedicines based on host-guest interactions of cyclodextrins.Exploration (Beijing, China) · 2023Review
- Folate-Mediated Paclitaxel Nanodelivery Systems: A Comprehensive Review.Turkish journal of pharmaceutical sciences · 2023Article
- Biomacromolecules as carriers in drug delivery and tissue engineering.Acta pharmaceutica Sinica. B · 2018Review
- Docetaxel-Loaded Nanoparticles Assembled from β-Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells.Frontiers in pharmacology · 2017Article
- Controllable drug uptake and nongenomic response through estrogen-anchored cyclodextrin drug complex.International journal of nanomedicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy and applicability of anticancer drugs are greatly restricted by severe systemic toxicities and drug resistance. Targeting drug delivery strategies have been developed to prevent the shortcomings of chemotherapy. Among various approaches to specifically target drug-loaded carrier systems to the required pathological sites, ligand-attached cyclodextrin-based targeting complexes are a promising drug delivery system, which is achieved mainly through specific molecular interactions between the drugs and cell surface receptors. The principal targeting tactics include conjugation of cyclodextrin with targeting moieties or encapsulation drugs in cyclodextrins. The cyclodextrin-based supramolecules, polymers, or nanoparticles bearing bioactive substances such as folate, estrogens, carbohydrates, peptides, etc. have been reviewed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.